{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:46:51Z","timestamp":1787168811429,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent advancements in high-throughput sequencing have validated the accuracy, safety, and effectiveness of non-invasive prenatal testing (NIPT) for Down syndrome (DS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study aims to assess the effectiveness and economic implications of NIPT versus second-trimester serum screening (STSS) for DS and the different screening strategies through retrospectively analyzing data from 140,472 pregnant women who completed both NIPT and STSS (provided for free by local public welfare programs) between March 1, 2018 and December 31, 2020. Data were categorized into eight groups based on different screening strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The sensitivity, specificity, and positive predictive value of NIPT for detecting trisomy 21 were significantly higher compared with those of STSS. The universal NIPT screening strategy demonstrated the best effectiveness, detecting 163 DS cases with the highest net benefit and a cost-effectiveness ratio of 1:9.53. The STSS and NIPT combined screening strategy detected 128 DS cases with the lowest cost-effectiveness at RMB 341,800. The incremental cost-effectiveness ratio of the universal NIPT screening strategy was RMB 1,186,200, significantly lower than the socioeconomic burden associated with a DS case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NIPT demonstrated significantly superior testing performance compared to STSS. At a unit cost of RMB 600, the universal NIPT screening strategy is the most effective and holds substantial health economic value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1535381","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:14:15Z","timestamp":1746782055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of different screening strategies for Down syndrome: a real-world analysis in 140,472 women"],"prefix":"10.3389","volume":"13","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Linpeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinmei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/1471-0528.14009","article-title":"Performance of prenatal screening using maternal serum and ultrasound markers for down syndrome in Chinese women: a systematic review and meta-analysis","volume":"123","author":"Tu","year":"2016","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/uog.17484","article-title":"Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis","volume":"50","author":"Gil","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/uog.14792","article-title":"Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies","volume":"45","author":"Zhang","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","article-title":"Cell-free DNA analysis for noninvasive examination of trisomy","volume":"372","author":"Norton","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/gim.2016.97","article-title":"Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics","volume":"18","author":"Gregg","year":"2016","journal-title":"Genet Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/AOG.0000000000004084","article-title":"Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226","volume":"136","author":"Rose","year":"2020","journal-title":"Obstet Gynecol"},{"key":"ref7","volume-title":"UK NSC non-invasive prenatal testing (NIPT) recommendation","author":"Committee","year":"2016"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/AOG.0000000000001385","article-title":"Aneuploidy screening in pregnancy","volume":"128","author":"Dashe","year":"2016","journal-title":"Obstet Gynecol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ajhg.2019.10.005","article-title":"TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands","volume":"105","author":"van der Meij","year":"2019","journal-title":"Am J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41436-021-01101-4","article-title":"Outcome of publicly funded nationwide first-tier noninvasive prenatal screening","volume":"23","author":"Van Den Bogaert","year":"2021","journal-title":"Genet Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11427-019-9600-0","article-title":"Evidence of compliance with and effectiveness of guidelines for noninvasive prenatal testing in China: a retrospective study of 189,809 cases","volume":"63","author":"Tian","year":"2020","journal-title":"Sci China Life Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/pd.4160","article-title":"Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population","volume":"33","author":"Song","year":"2013","journal-title":"Prenat Diagn"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pd.5111","article-title":"Systematic review and meta-analysis of non-invasive prenatal DNA testing for trisomy 21: implications for implementation in China","volume":"37","author":"Jin","year":"2017","journal-title":"Prenat Diagn"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0131402","DOI":"10.1371\/journal.pone.0131402","article-title":"A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States","volume":"10","author":"Walker","year":"2015","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/uog.14693","article-title":"Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies","volume":"45","author":"Evans","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e005922","DOI":"10.1136\/bmjopen-2014-005922","article-title":"Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis","volume":"4","author":"Neyt","year":"2014","journal-title":"BMJ Open"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejogrb.2014.08.028","article-title":"The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis","volume":"182","author":"Beulen","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e046582","DOI":"10.1136\/bmjopen-2020-046582","article-title":"Introducing the non-invasive prenatal testing for detection of down syndrome in China: a cost-effectiveness analysis","volume":"11","author":"Shang","year":"2021","journal-title":"BMJ Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pd.4511","article-title":"A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for down syndrome","volume":"35","author":"Walker","year":"2015","journal-title":"Prenat Diagn"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"870543","DOI":"10.3389\/fpubh.2022.870543","article-title":"A cost-effectiveness analysis of screening strategies involving non-invasive prenatal testing for trisomy 21","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"ref21","volume-title":"\u957f\u6c99\u5e02\u5065\u5eb7\u6c11\u751f\u9879\u76ee\u2014\u514d\u8d39\u5b55\u5987\u5916\u5468\u8840\u80ce\u513f\u6e38\u79bbDNA\u4ea7\u524d\u7b5b\u67e5\u4e0e\u8bca\u65ad\u5de5\u4f5c\u5b9e\u65bd\u65b9\u6848. 2021.06.15","year":"2021"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3109\/14767058.2015.1038703","article-title":"Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis","volume":"29","author":"Fairbrother","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e35614","DOI":"10.1097\/MD.0000000000035614","article-title":"A review of cost-effectiveness analysis: from theory to clinical practice","volume":"102","author":"Brand\u00e3o","year":"2023","journal-title":"Medicine"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1535381\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:14:16Z","timestamp":1746782056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1535381\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":23,"alternative-id":["10.3389\/fpubh.2025.1535381"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1535381","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1535381"}}